Chiesi Group entered an exclusive collaboration and license with Arbor Biotechnologies to develop Arbor’s lead gene editing candidate ABO‑101 for primary hyperoxaluria type 1 (PH1) and to access Arbor’s editing platform for additional rare liver disease targets. The agreement could generate more than $2.1 billion to Arbor through development and commercial milestones. ABO‑101 is an in‑vivo, liver‑directed CRISPR Cas12i2 therapy delivered via lipid nanoparticles designed to permanently knock out HAO1 and reduce oxalate production in PH1 patients; a Phase I/II trial is underway. Chiesi will co‑develop the program and has options on further targets using Arbor’s platform. The deal represents Chiesi’s first foray into gene editing and underscores pharma interest in one‑time, liver‑directed editing approaches for rare metabolic disorders. Commercialization plans and global development responsibilities were outlined with an emphasis on building Chiesi’s rare‑disease pipeline while leveraging Arbor’s editing innovations.